China Shineway Pharmaceutical Group Limited

HKSE 2877.HK

China Shineway Pharmaceutical Group Limited Net Income Margin for the year ending December 31, 2023: 21.47%

China Shineway Pharmaceutical Group Limited Net Income Margin is 21.47% for the year ending December 31, 2023, a 17.33% change year over year. Net Income Ratio, also known as the profit margin, is the ratio of net income to net sales, showing the percentage of revenue that remains as profit after all expenses are deducted.

China Shineway Pharmaceutical Group Limited Net Income Margin for the year ending December 31, 2022 was 18.30%, a 5.94% change year over year.
China Shineway Pharmaceutical Group Limited Net Income Margin for the year ending December 31, 2021 was 17.27%, a 55.44% change year over year.
China Shineway Pharmaceutical Group Limited Net Income Margin for the year ending December 31, 2020 was 11.11%, a -40.25% change year over year.
China Shineway Pharmaceutical Group Limited Net Income Margin for the year ending December 31, 2019 was 18.59%, a -5.53% change year over year.

Key data

Date	Net Income Margin	EBITDA Margin	EBIT Margin	EBITDA

HKSE: 2877.HK

China Shineway Pharmaceutical Group Limited

CEO	Mr. Zhenjiang Li
IPO Date	Dec. 2, 2004
Location	China
Headquarters	No. 168 Shiluan Street
Employees	3,232
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Cosmetics Drugstores & Retail Pharmacies Personal Care

Description

China Shineway Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and trade of Chinese medicines in the People's Republic of China and Hong Kong. The company offers modern Chinese medicines in the form of soft capsules, granules, and injections, as well as TCM Formula Granules in various therapeutic areas, including cardio-cerebrovascular, anti-viral, orthopedics, pediatrics, gynecology, and gastroenterology. It also trades in agricultural products. The company was incorporated in 2004 and is headquartered in Shijiazhuang, the People's Republic of China. China Shineway Pharmaceutical Group Limited is a subsidiary of Forway Investment Limited.

Key trends

Past 5 years